Studies in Advanced NSCLC of Maintenance Pemetrexed and Erlotinib and of BIBW 2992 or MetMAb Targeted Therapy for Acquired Resistance to Erlotinib and Gefitinib


Studies in Advanced NSCLC of Maintenance Pemetrexed and Erlotinib and of BIBW 2992 or MetMAb Targeted Therapy for Acquired Resistance to Erlotinib and Gefitinib
Slides from presentations at ASCO 2011 and comments from Edward S Kim, MD and Thomas J Lynch Jr, MD

Paz-Ares L et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). Proc ASCO 2011;Abstract CRA7510.

Dr Kim is Associate Professor of Medicine, Chief of the Section of Head and Neck Medical Oncology and Director of Clinical Research Operations at The University of Texas MD Anderson Cancer Center in Houston, Texas.